Clinical Evaluation of Tumour Marker Combinations in the Differential Diagnosis of Benign and Malignant Liver Disease

CEA, CA19-9 and CA50 are tumour associated antigens defined by monoclonal antibodies which have been raised against adenocarcinoma cell lines. The aim of this study was to determine whether their combined use could improve diagnostic accuracy in patients with primary and secondary liver tumours. An...

Descripción completa

Detalles Bibliográficos
Autores principales: Lucarotti, M. E., Rothnie, N. D., Kelly, S. B., Hershman, M. J., Johanssen, C., Nilsson, O., Lindholm, L., Wood, C. B., Williamson, R. C. N., Habib, N. A.
Formato: Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 1991
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2442938/
https://www.ncbi.nlm.nih.gov/pubmed/1777407
http://dx.doi.org/10.1155/1991/23874

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2442938/
https://www.ncbi.nlm.nih.gov/pubmed/1777407
http://dx.doi.org/10.1155/1991/23874

Ejemplares similares